David C.W. Lau, MD, PhD
University of Calgary Cumming School
Biography & Research Background
David C.W. Lau, MD, PhD is based at the University of Calgary Cumming School of Medicine. He led the Phase 2 dose-finding study of cagriniltide monotherapy and the Phase 1b safety/tolerability trial of cagriniltide with semaglutide; both were published in The Lancet (2021). David C.W. Lau is being referenced as one of the leading scientists involved in cagriniltide research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Cited In These Research Profiles (1)
David C.W. Lau, MD, PhD is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
David C.W. Lau, MD, PhD is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.